Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(14.29%)
USD 0.0
(14.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.85 Million USD | 20.06% |
| 2022 | -16.5 Million USD | -80.14% |
| 2021 | -1.51 Million USD | 41.83% |
| 2020 | -2.26 Million USD | 14.11% |
| 2019 | -10.57 Million USD | 50.87% |
| 2018 | -588.5 Thousand USD | -54.11% |
| 2017 | -4.58 Million USD | 47.09% |
| 2016 | -5.39 Million USD | -530.63% |
| 2015 | -2.54 Million USD | -63.46% |
| 2014 | -2.17 Million USD | 65.53% |
| 2013 | -2.61 Million USD | -30.12% |
| 2012 | -1.7 Million USD | -1747.4% |
| 2011 | - USD | -36.48% |
| 2010 | - USD | 79.5% |
| 2009 | -330 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -250.23 Thousand USD | -5.0% |
| 2024 Q1 | -238.31 Thousand USD | 77.68% |
| 2023 Q4 | -624.32 Thousand USD | -95.99% |
| 2023 Q1 | -376.75 Thousand USD | -11.56% |
| 2023 Q3 | -318.55 Thousand USD | 67.66% |
| 2023 Q2 | -984.9 Thousand USD | -161.42% |
| 2023 FY | - USD | 20.06% |
| 2022 Q3 | -365.92 Thousand USD | 79.84% |
| 2022 Q1 | -324.03 Thousand USD | -52.8% |
| 2022 FY | - USD | -80.14% |
| 2022 Q4 | -337.71 Thousand USD | 7.71% |
| 2022 Q2 | -1.81 Million USD | -460.13% |
| 2021 Q2 | -408.32 Thousand USD | 4.4% |
| 2021 FY | - USD | 41.83% |
| 2021 Q1 | -427.13 Thousand USD | 53.29% |
| 2021 Q4 | -212.06 Thousand USD | 60.03% |
| 2021 Q3 | -530.52 Thousand USD | -29.93% |
| 2020 Q1 | -516.25 Thousand USD | 90.24% |
| 2020 FY | - USD | 14.11% |
| 2020 Q2 | -439.19 Thousand USD | 14.93% |
| 2020 Q3 | -843.07 Thousand USD | -91.96% |
| 2020 Q4 | -914.52 Thousand USD | -8.48% |
| 2019 Q4 | -5.28 Million USD | -188.51% |
| 2019 FY | - USD | 50.87% |
| 2019 Q1 | -680.87 Thousand USD | 84.71% |
| 2019 Q2 | 4.64 Million USD | 782.21% |
| 2019 Q3 | -1.83 Million USD | -139.47% |
| 2018 Q3 | 2.5 Million USD | 273.73% |
| 2018 Q1 | -3.04 Million USD | 41.3% |
| 2018 FY | - USD | -54.11% |
| 2018 Q4 | -4.45 Million USD | -277.41% |
| 2018 Q2 | -1.44 Million USD | 52.52% |
| 2017 Q2 | -7.53 Million USD | -251.47% |
| 2017 Q1 | 4.97 Million USD | 647.41% |
| 2017 FY | - USD | 47.09% |
| 2017 Q4 | -5.18 Million USD | -245.12% |
| 2017 Q3 | 3.57 Million USD | 147.39% |
| 2016 Q3 | -1.31 Million USD | 57.83% |
| 2016 Q1 | -2.55 Million USD | -4860.38% |
| 2016 Q4 | -908.83 Thousand USD | 30.69% |
| 2016 FY | - USD | -530.63% |
| 2016 Q2 | -3.1 Million USD | -21.65% |
| 2015 Q3 | -466.23 Thousand USD | 9.64% |
| 2015 FY | - USD | -63.46% |
| 2015 Q4 | 53.68 Thousand USD | 111.52% |
| 2015 Q2 | -515.96 Thousand USD | -20.56% |
| 2015 Q1 | -427.99 Thousand USD | -134.43% |
| 2014 Q2 | -815.25 Thousand USD | -44.56% |
| 2014 FY | - USD | 65.53% |
| 2014 Q1 | -563.94 Thousand USD | -87.76% |
| 2014 Q4 | 1.24 Million USD | 298.22% |
| 2014 Q3 | -627.18 Thousand USD | 23.07% |
| 2013 Q4 | -300.34 Thousand USD | 28.18% |
| 2013 FY | - USD | -30.12% |
| 2013 Q1 | -1.02 Million USD | -126.03% |
| 2013 Q2 | -476.32 Thousand USD | 53.38% |
| 2013 Q3 | -418.17 Thousand USD | 12.21% |
| 2012 Q4 | -452.02 Thousand USD | -25.63% |
| 2012 FY | - USD | -1747.4% |
| 2012 Q1 | -413.38 Thousand USD | -1966.92% |
| 2012 Q2 | -383.75 Thousand USD | 7.17% |
| 2012 Q3 | -359.8 Thousand USD | 6.24% |
| 2011 Q3 | -20 Thousand USD | 0.0% |
| 2011 FY | - USD | -36.48% |
| 2011 Q4 | -20 Thousand USD | 0.0% |
| 2010 FY | - USD | 79.5% |
| 2010 Q4 | -20 Thousand USD | 0.0% |
| 2010 Q3 | -20 Thousand USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 112.464% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 249.333% |
| SQZ Biotechnologies Company | -64.14 Million USD | 113.804% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 150.972% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 90.585% |
| Mesoblast Limited | -62.38 Million USD | 114.191% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 676.401% |
| Genus plc | 73.7 Million USD | 87.987% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 233.915% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 349.614% |
| Marizyme, Inc. | -34.28 Million USD | 125.827% |
| ContraFect Corporation | -64.99 Million USD | 113.621% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 200.933% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 295.612% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 731.599% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 434.807% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 481.002% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 1809.076% |
| Accustem Sciences Inc. | -3.74 Million USD | 336.327% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 118.359% |
| EV Biologics, Inc. | -1.26 Million USD | 798.728% |
| Q BioMed Inc. | -617.62 Thousand USD | 1533.517% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -147.867% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 1500.019% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 487.562% |
| Biomind Labs Inc. | -1.03 Million USD | 955.813% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 10.359% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 223.634% |
| Skye Bioscience, Inc. | -13.54 Million USD | 165.354% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 695.249% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 35515.204% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 327.937% |
| IMV Inc. | -35.52 Million USD | 124.924% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 155.79% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 453.874% |
| GB Sciences, Inc. | -1.41 Million USD | 723.558% |
| Alpha Cognition Inc. | -9.7 Million USD | 191.224% |
| HST Global, Inc. | -5303.00 USD | 167058.344% |
| CSL Limited | 4.78 Billion USD | 99.815% |
| Halberd Corporation | -74.27 Thousand USD | 12019.656% |
| Enzolytics Inc. | -2.12 Million USD | 517.233% |
| Resverlogix Corp. | -11.74 Million USD | 175.403% |
| Affymax, Inc. | -14.29 Million USD | 161.936% |
| SYBLEU INC | -141.57 Thousand USD | 6353.965% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 389.055% |
| argenx SE | -216.02 Million USD | 104.099% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 115.999% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -627.51% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 690.684% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -2237.057% |
| AVAX Technologies, Inc. | -6.11 Million USD | 244.844% |
| Zenith Capital Corp. | -8.6 Million USD | 202.879% |
| Genscript Biotech Corporation | -248.71 Million USD | 103.56% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 50922.576% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 461.902% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 5129.873% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 122.337% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 406.114% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 946.191% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -131574.613% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 605.932% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 560.917% |
| BioStem Technologies, Inc. | -7.55 Million USD | 217.212% |
| ONE Bio Corp. | 13.61 Million USD | 34.961% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 4989.226% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 530.423% |
| Agentix Corp. | -1.37 Million USD | 745.436% |
| LadRx Corporation | 412.28 Thousand USD | -2047.506% |
| Cell Source, Inc. | -4.27 Million USD | 307.226% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 2511.028% |
| Regen BioPharma, Inc. | 1.46 Million USD | -503.961% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 1044.961% |
| NovAccess Global Inc. | -1.03 Million USD | 955.608% |
| Itoco Inc. | -1.86 Million USD | 573.72% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 2432.28% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 893.351% |
| Kadimastem Ltd | -2.62 Million USD | 437.367% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 3802.196% |
| CytoDyn Inc. | -18.02 Million USD | 149.109% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 11303.23% |
| Mobile Lads Corp. | -2.24 Million USD | 495.055% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 72500.041% |
| Qrons Inc. | -40.08 Thousand USD | 22189.771% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 1922.978% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -1578.659% |
| Rebus Holdings, Inc. | -951 Thousand USD | 1030.999% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 933.683% |
| International Stem Cell Corporation | 202 Thousand USD | -4283.07% |
| Bioxytran, Inc. | -3.82 Million USD | 331.766% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 16919.531% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 459.628% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 124.684% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 19775.113% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 423.367% |
| Neutra Corp. | -181.24 Thousand USD | 4984.937% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 143.92% |
| PureTech Health plc | -11.62 Million USD | 176.149% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 143.923% |
| IXICO plc | -707 Thousand USD | 1352.306% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 215.209% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 118.313% |
| CSL Limited | 4.73 Billion USD | 99.813% |
| Cellectis S.A. | -92.63 Million USD | 109.558% |